RBC Life Sciences Announces MPM Medical Expansion into Latin America

IRVING, Texas--(Business Wire)--
RBC Life Sciences, Inc. (OTCBB: RBCL) today announced that its
wholly owned subsidiary, MPM Medical, Inc., has entered into a 15-year
exclusive distributorship agreement with Glenmark, Farmaceutica LTDA,
a pharmaceutical distributor located in Sao Do Campo - SP, Brazil.
Through this distribution agreement Glenmark retains exclusive
marketing and distribution rights in Brazil for two of MPM's unique
wound care products, which are used by oncology patients suffering
from adverse reactions to certain oncology treatments.

"We are extremely pleased to announce this partnership with
Glenmark Farmaceutica for distribution of our products in Latin
America," stated Paul R. Miller, President of MPM Medical. "This
agreement represents our first significant expansion into the
international market place. Even more so, we are delighted that we can
now offer our exceptional healing products to more people who are in
need of relief."

Under this agreement, Glenmark will market RadiaPlex Gel, a
hydrogel uniquely designed to protect a patient's skin from radiation
reactions and to assist in healing the skin if a radiation reaction
does occur, as well as OraMagicRx Oral Wound Rinse, a product designed
to relieve pain associated with mouth sores that often develop as a
result of radiation and chemotherapy treatments.

RBC Life Sciences develops, manufactures and markets high quality
nutritional supplements and personal care products to a growing
population of consumers seeking wellness and a healthy lifestyle.
Under its MPM Medical brand, RBC also develops and markets to health
care professionals in the United States proprietary prescription and
nonprescription products for advanced wound care and pain management.
All products are tested for quality assurance in-house, and by outside
independent laboratories, to comply with regulations in the U.S. and
in more than thirty countries in which the products are distributed.

The statements above, other than statements of historical fact,
may be forward-looking. Actual events will be dependent upon a number
of factors and risks including but not limited to changes in plans by
the Company's management, delays or problems in production, changes in
the regulatory process, changes in market trends, and a number of
other factors and risks described from time to time in the Company's
filings with the Securities and Exchange Commission.

Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
gdebusk@halliburtonir.com
or
Chase Zavoina, 972-458-8000
czavoina@halliburtonir.com
or
Jeff Elliott, 972-458-8000
jelliott@halliburtonir.com

Copyright Business Wire 2008